$850 million investment in Fujifilm Diosynth Biotechnologies

30 June 2021

Japan’s FUJIFILM Corporation (TYO: 4901) today announced a 90 billion yen ($850 million) investment package to accelerate the growth of its core Bio Contract Development and Manufacturing Organization (CDMO) subsidiary, Fujifilm Diosynth Biotechnologies.

Fujifilm Diosynth Biotechnologies is an industry-leading biologics CDMO with over 30years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules and viral products expressed in a wide array of microbial, mammalian, and host/virus systems.

FUJIFILM Corp is steadily expanding its Bio CDMO business by investing in Fujifilm Diosynth Biotechnologies’ strength in contract development and manufacturing to increase capacity to meet the market demands for biopharmaceuticals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK